View ValuationEuroplasma 将来の成長Future 基準チェック /06現在、 Europlasmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Commercial Services 収益成長15.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (52% average weekly change). Negative equity (-€21m). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (488% increase in shares outstanding). Market cap is less than US$10m (€13.5k market cap, or US$15.7k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).お知らせ • Aug 14Europlasma S.A., Annual General Meeting, Sep 23, 2025Europlasma S.A., Annual General Meeting, Sep 23, 2025. Location: cite de la photonique, batiment sirah, 3 5 allee des lumieres, pessac France分析記事 • Aug 08Take Care Before Jumping Onto Europlasma S.A. (EPA:ALEUP) Even Though It's 35% CheaperENXTPA:ALEUP 1 Year Share Price vs Fair Value Explore Europlasma's Fair Values from the Community and select yours...分析記事 • Jun 24Investors Give Europlasma S.A. (EPA:ALEUP) Shares A 32% HidingUnfortunately for some shareholders, the Europlasma S.A. ( EPA:ALEUP ) share price has dived 32% in the last thirty...New Risk • Jun 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.38m (US$9.62m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€12m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-€11m). Earnings have declined by 9.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 645x increase in shares outstanding). Market cap is less than US$10m (€8.38m market cap, or US$9.62m).Reported Earnings • Jun 17Full year 2024 earnings released: €0.015 loss per share (vs €1,048 loss in FY 2023)Full year 2024 results: €0.015 loss per share. Revenue: €41.9m (up 171% from FY 2023). Net loss: €15.3m (loss widened 3.7% from FY 2023).New Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Shareholders have been substantially diluted in the past year (over 1321x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€9.82m market cap, or US$10.9m).お知らせ • Apr 30Europlasma S.A. (ENXTPA:ALEUP) acquired Fonderies de Bretagne.Europlasma S.A. (ENXTPA:ALEUP) acquired Fonderies de Bretagne on April 28, 2025. The Commercial Court of Rennes has approved the deal. Europlasma S.A. (ENXTPA:ALEUP) completed the acquisition of Fonderies de Bretagne on April 28, 2025.分析記事 • Mar 26A Piece Of The Puzzle Missing From Europlasma S.A.'s (EPA:ALEUP) 50% Share Price ClimbEuroplasma S.A. ( EPA:ALEUP ) shareholders are no doubt pleased to see that the share price has bounced 50% in the last...分析記事 • Oct 08Investors Continue Waiting On Sidelines For Europlasma S.A. (EPA:ALEUP)There wouldn't be many who think Europlasma S.A.'s ( EPA:ALEUP ) price-to-sales (or "P/S") ratio of 0.1x is worth a...お知らせ • Jul 23Europlasma S.A., Annual General Meeting, Sep 24, 2024Europlasma S.A., Annual General Meeting, Sep 24, 2024. Location: cite de la photonique batiment sirah, 3 5 allee des lumieres, pessac FranceNew Risk • May 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (85% average weekly change). Negative equity (-€362k). Shareholders have been substantially diluted in the past year (over 2086x increase in shares outstanding). Market cap is less than US$10m (€2.97m market cap, or US$3.21m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).分析記事 • May 30Even With A 74% Surge, Cautious Investors Are Not Rewarding Europlasma S.A.'s (EPA:ALEUP) Performance CompletelyEuroplasma S.A. ( EPA:ALEUP ) shareholders are no doubt pleased to see that the share price has bounced 74% in the last...Reported Earnings • May 27Full year 2023 earnings released: €0.21 loss per share (vs €26.32 loss in FY 2022)Full year 2023 results: €0.21 loss per share (improved from €26.32 loss in FY 2022). Revenue: €17.4m (up 17% from FY 2022). Net loss: €14.7m (loss narrowed 7.4% from FY 2022).New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (82% average weekly change). Negative equity (-€362k). Shareholders have been substantially diluted in the past year (over 328x increase in shares outstanding). Market cap is less than US$10m (€2.29m market cap, or US$2.47m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).分析記事 • Feb 28Investors Give Europlasma S.A. (EPA:ALEUP) Shares A 42% HidingTo the annoyance of some shareholders, Europlasma S.A. ( EPA:ALEUP ) shares are down a considerable 42% in the last...New Risk • Oct 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€362k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€104k free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-€362k). Shareholders have been substantially diluted in the past year (over 1502x increase in shares outstanding). Market cap is less than US$10m (€334.4k market cap, or US$353.4k).分析記事 • Apr 18Europlasma S.A. (EPA:ALEUP) Stock's 57% Dive Might Signal An Opportunity But It Requires Some ScrutinyEuroplasma S.A. ( EPA:ALEUP ) shares have retraced a considerable 57% in the last month, reversing a fair amount of...お知らせ • Feb 07Europlasma S.A. announced that it has received €1.5 million in fundingEuroplasma S.A. announced a private placement of common shares for the gross proceeds of €1.5 million in a round of funding on February 6, 2023. The company issued common shares in the transaction.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). CEO & Chairman Jérôme Garnache-Creuillot was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Oct 26First half 2022 earnings released: €0.012 loss per share (vs €0.68 loss in 1H 2021)First half 2022 results: €0.012 loss per share (improved from €0.68 loss in 1H 2021). Revenue: €7.78m (up 92% from 1H 2021). Net loss: €2.44m (loss narrowed 78% from 1H 2021).Reported Earnings • May 01Full year 2021 earnings released: €0.42 loss per share (vs €0.95 loss in FY 2020)Full year 2021 results: €0.42 loss per share. Revenue: €11.8m (up 80% from FY 2020). Net loss: €12.7m (loss widened 28% from FY 2020).Board Change • Apr 27No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Laurent Collet-Billon is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Nov 02First half 2021 earnings releasedThe company reported a poor first half result with increased losses, weaker revenues and weaker control over costs. First half 2021 results: Revenue: €3.02m (down 3.8% from 1H 2020). Net loss: €11.1m (loss widened 2.4% from 1H 2020).Reported Earnings • Apr 25Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €3.80m (up 15% from FY 2019). Net loss: €9.88m (loss narrowed 6.9% from FY 2019).Is New 90 Day High Low • Feb 24New 90-day low: €1.58The company is down 33% from its price of €2.38 on 26 November 2020. The French market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 9.0% over the same period.Is New 90 Day High Low • Jan 28New 90-day low: €1.74The company is down 25% from its price of €2.31 on 30 October 2020. The French market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 31% over the same period.Reported Earnings • Oct 16First half earnings releasedOver the last 12 months the company has reported total losses of €8.89m, with losses narrowing by 84% from the prior year.Reported Earnings • Oct 14First half earnings releasedOver the last 12 months the company has reported total losses of €8.89m, with losses narrowing by 84% from the prior year.Is New 90 Day High Low • Oct 14New 90-day low: €2.64The company is down 4.0% from its price of €2.75 on 16 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 3.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Europlasma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ENXTPA:ALEUP - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202560-44-26-23N/A3/31/202551-30-19-17N/A12/31/202443-15-12-11N/A9/30/202433-13-11-9N/A6/30/202424-10-9-8N/A3/31/202420-12-10-9N/A12/31/202315-15-12-10N/A9/30/202315-15-6-4N/A6/30/202314-1602N/A3/31/202315-16-4-2N/A12/31/202215-16-8-5N/A9/30/202215-10-16-12N/A6/30/202215-4-24-19N/A3/31/202213-8-24-19N/A12/31/202111-13-24-18N/A9/30/20219-11-23-18N/A6/30/20217-10-22-19N/A3/31/20217-10-20-15N/A12/31/20207-10-17-12N/A9/30/20205-9-13-9N/A6/30/20203-9-9-5N/A3/31/20203-10-8-6N/A12/31/20193-11-7-7N/A9/30/20197-33-10-8N/A6/30/201911-56-12-10N/A3/31/201912-55N/A-11N/A12/31/201814-54N/A-13N/A9/30/201816-38N/A-13N/A6/30/201817-21N/A-12N/A3/31/201816-22N/A-12N/A12/31/201716-22N/A-11N/A9/30/201713-21N/A-10N/A6/30/201710-19N/A-10N/A3/31/201711-18N/A-9N/A12/31/201612-17N/A-8N/A9/30/201613-16N/A-8N/A6/30/201614-15N/A-8N/A3/31/201615-16N/A-10N/A12/31/201516-16N/A-12N/A9/30/201515-22N/A-14N/A6/30/201513-28N/A-16N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ALEUPの予測収益成長が 貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ALEUPの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ALEUPの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ALEUPの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ALEUPの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ALEUPの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCommercial-services 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 04:23終値2026/06/09 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Europlasma S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (52% average weekly change). Negative equity (-€21m). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (488% increase in shares outstanding). Market cap is less than US$10m (€13.5k market cap, or US$15.7k). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
お知らせ • Aug 14Europlasma S.A., Annual General Meeting, Sep 23, 2025Europlasma S.A., Annual General Meeting, Sep 23, 2025. Location: cite de la photonique, batiment sirah, 3 5 allee des lumieres, pessac France
分析記事 • Aug 08Take Care Before Jumping Onto Europlasma S.A. (EPA:ALEUP) Even Though It's 35% CheaperENXTPA:ALEUP 1 Year Share Price vs Fair Value Explore Europlasma's Fair Values from the Community and select yours...
分析記事 • Jun 24Investors Give Europlasma S.A. (EPA:ALEUP) Shares A 32% HidingUnfortunately for some shareholders, the Europlasma S.A. ( EPA:ALEUP ) share price has dived 32% in the last thirty...
New Risk • Jun 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.38m (US$9.62m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€12m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-€11m). Earnings have declined by 9.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 645x increase in shares outstanding). Market cap is less than US$10m (€8.38m market cap, or US$9.62m).
Reported Earnings • Jun 17Full year 2024 earnings released: €0.015 loss per share (vs €1,048 loss in FY 2023)Full year 2024 results: €0.015 loss per share. Revenue: €41.9m (up 171% from FY 2023). Net loss: €15.3m (loss widened 3.7% from FY 2023).
New Risk • May 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (35% average weekly change). Shareholders have been substantially diluted in the past year (over 1321x increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€9.82m market cap, or US$10.9m).
お知らせ • Apr 30Europlasma S.A. (ENXTPA:ALEUP) acquired Fonderies de Bretagne.Europlasma S.A. (ENXTPA:ALEUP) acquired Fonderies de Bretagne on April 28, 2025. The Commercial Court of Rennes has approved the deal. Europlasma S.A. (ENXTPA:ALEUP) completed the acquisition of Fonderies de Bretagne on April 28, 2025.
分析記事 • Mar 26A Piece Of The Puzzle Missing From Europlasma S.A.'s (EPA:ALEUP) 50% Share Price ClimbEuroplasma S.A. ( EPA:ALEUP ) shareholders are no doubt pleased to see that the share price has bounced 50% in the last...
分析記事 • Oct 08Investors Continue Waiting On Sidelines For Europlasma S.A. (EPA:ALEUP)There wouldn't be many who think Europlasma S.A.'s ( EPA:ALEUP ) price-to-sales (or "P/S") ratio of 0.1x is worth a...
お知らせ • Jul 23Europlasma S.A., Annual General Meeting, Sep 24, 2024Europlasma S.A., Annual General Meeting, Sep 24, 2024. Location: cite de la photonique batiment sirah, 3 5 allee des lumieres, pessac France
New Risk • May 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (85% average weekly change). Negative equity (-€362k). Shareholders have been substantially diluted in the past year (over 2086x increase in shares outstanding). Market cap is less than US$10m (€2.97m market cap, or US$3.21m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
分析記事 • May 30Even With A 74% Surge, Cautious Investors Are Not Rewarding Europlasma S.A.'s (EPA:ALEUP) Performance CompletelyEuroplasma S.A. ( EPA:ALEUP ) shareholders are no doubt pleased to see that the share price has bounced 74% in the last...
Reported Earnings • May 27Full year 2023 earnings released: €0.21 loss per share (vs €26.32 loss in FY 2022)Full year 2023 results: €0.21 loss per share (improved from €26.32 loss in FY 2022). Revenue: €17.4m (up 17% from FY 2022). Net loss: €14.7m (loss narrowed 7.4% from FY 2022).
New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (82% average weekly change). Negative equity (-€362k). Shareholders have been substantially diluted in the past year (over 328x increase in shares outstanding). Market cap is less than US$10m (€2.29m market cap, or US$2.47m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
分析記事 • Feb 28Investors Give Europlasma S.A. (EPA:ALEUP) Shares A 42% HidingTo the annoyance of some shareholders, Europlasma S.A. ( EPA:ALEUP ) shares are down a considerable 42% in the last...
New Risk • Oct 29New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€362k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€104k free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-€362k). Shareholders have been substantially diluted in the past year (over 1502x increase in shares outstanding). Market cap is less than US$10m (€334.4k market cap, or US$353.4k).
分析記事 • Apr 18Europlasma S.A. (EPA:ALEUP) Stock's 57% Dive Might Signal An Opportunity But It Requires Some ScrutinyEuroplasma S.A. ( EPA:ALEUP ) shares have retraced a considerable 57% in the last month, reversing a fair amount of...
お知らせ • Feb 07Europlasma S.A. announced that it has received €1.5 million in fundingEuroplasma S.A. announced a private placement of common shares for the gross proceeds of €1.5 million in a round of funding on February 6, 2023. The company issued common shares in the transaction.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). CEO & Chairman Jérôme Garnache-Creuillot was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 26First half 2022 earnings released: €0.012 loss per share (vs €0.68 loss in 1H 2021)First half 2022 results: €0.012 loss per share (improved from €0.68 loss in 1H 2021). Revenue: €7.78m (up 92% from 1H 2021). Net loss: €2.44m (loss narrowed 78% from 1H 2021).
Reported Earnings • May 01Full year 2021 earnings released: €0.42 loss per share (vs €0.95 loss in FY 2020)Full year 2021 results: €0.42 loss per share. Revenue: €11.8m (up 80% from FY 2020). Net loss: €12.7m (loss widened 28% from FY 2020).
Board Change • Apr 27No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Laurent Collet-Billon is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Nov 02First half 2021 earnings releasedThe company reported a poor first half result with increased losses, weaker revenues and weaker control over costs. First half 2021 results: Revenue: €3.02m (down 3.8% from 1H 2020). Net loss: €11.1m (loss widened 2.4% from 1H 2020).
Reported Earnings • Apr 25Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €3.80m (up 15% from FY 2019). Net loss: €9.88m (loss narrowed 6.9% from FY 2019).
Is New 90 Day High Low • Feb 24New 90-day low: €1.58The company is down 33% from its price of €2.38 on 26 November 2020. The French market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Jan 28New 90-day low: €1.74The company is down 25% from its price of €2.31 on 30 October 2020. The French market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 31% over the same period.
Reported Earnings • Oct 16First half earnings releasedOver the last 12 months the company has reported total losses of €8.89m, with losses narrowing by 84% from the prior year.
Reported Earnings • Oct 14First half earnings releasedOver the last 12 months the company has reported total losses of €8.89m, with losses narrowing by 84% from the prior year.
Is New 90 Day High Low • Oct 14New 90-day low: €2.64The company is down 4.0% from its price of €2.75 on 16 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Commercial Services industry, which is up 3.0% over the same period.